Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study

Gwen Murphy, Angelika Michel, Philip R. Taylor, Demetrius Albanes, Stephanie J. Weinstein, Jarmo Virtamo, Dominick Parisi, Kirk Snyder, Julia Butt, Katherine A. McGlynn, Jill Koshiol, Michael Pawlita, Gabriel Y. Lai, Christian C. Abnet, Sanford M. Dawsey, Neal D. Freedman – 2 May 2014 – Helicobacter have been detected in human bile and hepatobiliary tissue. Despite evidence that Helicobacter species promote gallstone formation and hepatobiliary tumors in laboratory studies, it remains unclear whether Helicobacter species contribute to these cancers in humans.

Tuberculosis in liver transplant recipients: Experience of a South Indian liver transplant center

Arikichenin Olithselvan, Srinivas Rajagopala, Mukul Vij, Vivekanandan Shanmugam, Naresh Shanmugam, Mohammed Rela – 30 April 2014 – Tuberculosis (TB) is a serious disease for liver transplant recipients (LTRs). Data on post–liver transplant TB from high‐burden countries are scant. The aims of this study were to describe the prevalence of TB in LTRs from a high‐prevalence area and to analyze the risk factors for the development of post–liver transplant TB. We performed a retrospective review of our database and a case‐control study of identified cases with TB and age‐matched LTRs without TB.

Comparative effectiveness of liver transplant strategies for end‐stage liver disease patients on renal replacement therapy

Yaojen Chang, Lorenzo Gallon, Colleen Jay, Kirti Shetty, Bing Ho, Josh Levitsky, Talia Baker, Daniela Ladner, John Friedewald, Michael Abecassis, Gordon Hazen, Anton I. Skaro – 29 April 2014 – There are complex risk‐benefit tradeoffs with different transplantation strategies for end‐stage liver disease patients on renal support.

Combined hepatocellular‐cholangiocarcinoma: A population‐level analysis of an uncommon primary liver tumor

Mattia Garancini, Paolo Goffredo, Fabio Pagni, Fabrizio Romano, Sanziana Roman, Julie Ann Sosa, Vittorio Giardini – 29 April 2014 – Combined hepatocellular‐cholangiocarcinoma (cHCC‐CC) is a rare primary liver cancer. Our aims were to analyze the demographic, clinical, and pathological characteristics of cHCC‐CC at a population level and to investigate the effects of these features as well as different management strategies on the prognosis. The Surveillance, Epidemiology, and End Results (SEER) database was analyzed for 1988‐2009.

Subscribe to